Form 8-K - Current report:
SEC Accession No. 0001104659-21-130339
Filing Date
2021-10-27
Accepted
2021-10-27 11:09:23
Documents
14
Period of Report
2021-10-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2131166d1_8k.htm   iXBRL 8-K 27660
2 EXHIBIT 99.1 tm2131166d1_ex99-1.htm EX-99.1 17599
3 GRAPHIC logo.jpg GRAPHIC 3306
  Complete submission text file 0001104659-21-130339.txt   227891

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nvax-20201027.xsd EX-101.SCH 3186
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20201027_lab.xml EX-101.LAB 34594
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20201027_pre.xml EX-101.PRE 22711
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2131166d1_8k_htm.xml XML 3483
Mailing Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 211351347
SIC: 2836 Biological Products, (No Diagnostic Substances)